Private Label Tampon FDA Roles: 510(k) Holder, Manufacturer, Relabeler and Importer

Quick answer: In a U.S. private-label tampon project, a supplier’s FDA establishment registration does not by itself show that your exact branded product is cleared. Before approving packaging or placing an order, map the exact 510(k) record, manufacturing site, specification developer, relabeler or repackager, initial importer, and U.S. agent. Record the legal name and responsibility of each party in writing.

The phrase “Does the factory have FDA?” compresses several different records and business roles into one question. That creates avoidable risk for brand owners, importers, distributors, and retail procurement teams. A better sourcing process separates product clearance, establishment registration, device listing, labeling activity, manufacturing, and import responsibilities.

This article is a procurement guide, not legal or regulatory advice. Have a qualified U.S. regulatory professional assess the exact device, entities, proposed changes, and sales route before commercial distribution.

Why “Does the factory have FDA?” is the wrong question

FDA treats menstrual tampons marketed in the United States as medical devices. The current FDA 510(k) guidance for menstrual tampons discusses product design and dimensions, component materials, absorbency, performance, microbiology, biocompatibility, and labeling. Those details relate to an exact device—not merely to a factory name or a generic product photo.

Several records may therefore be relevant to one private-label project:

a 510(k) number and the applicant shown in the public database;
an establishment registration for each entity that must register;
a device listing associated with the relevant establishment;
the physical manufacturing facility and its contracted role;
the entity that develops specifications or distributes the device under its own name;
the party that changes labels or packaging;
the initial importer for a foreign-manufactured device; and
the U.S. agent for a foreign establishment.

These items are connected, but they are not interchangeable. FDA also states that establishment registration and device listing do not denote approval, clearance, or authorization of the establishment or its devices.

The roles in a U.S. private-label tampon project

The public 510(k) database uses the term applicant. Buyers and suppliers often use 510(k) holder as commercial shorthand. Your due-diligence file and contracts should use the exact entity name shown in the FDA record and clearly state what that entity is responsible for.

Role	What it generally means	What the buyer should verify
510(k) applicant / commonly called holder	The entity named as applicant in the premarket notification record for the cleared device. It may or may not be the physical factory.	Exact K number, device name, applicant name, decision date, product code, public summary or statement, and relevance to the proposed product.
Specification developer	An entity that develops specifications for a device distributed under its own name but performs no manufacturing.	Who controls the finished specification, design changes, regulatory assessment, labeling, and supplier approval.
Contract or physical manufacturer	An establishment that manufactures a finished device to another establishment’s specifications, or the physical facility performing the defined manufacturing work.	Legal facility name and address, registered role, exact processes performed, approved specification, quality agreement, release responsibilities, and change control.
Relabeler	An entity that changes labeling content for distribution under its own name.	Who creates, reviews, approves, applies, and controls the private-label artwork and instructions; whether registration and listing duties apply.
Repackager	An entity that packages bulk product or changes the container or wrapper in which a finished device is distributed.	Where packaging changes occur, what packaging is changed, the registered role, process controls, traceability, and label reconciliation.
Initial importer	A U.S. entity that furthers the marketing of a device from a foreign manufacturer to the final U.S. consumer without repackaging or changing the container, wrapper, or labeling.	Legal importer name, establishment registration, manufacturer identification, import procedures, complaint handling, and regulatory reporting responsibilities.
U.S. agent	The U.S.-based contact designated by a foreign establishment to assist FDA communications.	Agent name and contact details, written appointment, and communication scope. Do not assume the U.S. agent is also the initial importer.
Wholesale distributor	An entity that distributes a finished device but does not manufacture, repackage, relabel, or otherwise change it.	Exact activity, chain of custody, traceability, and whether any additional activity changes its regulatory role.

A company can perform more than one role. Conversely, a sales website, contracting entity, factory, 510(k) applicant, importer, and U.S. agent can be different companies. The goal is not to force every role into one entity; it is to make the structure transparent and supported by records.

How to verify the 510(k) for the exact tampon

1. Ask for the exact K number

Do not accept “FDA registered,” a certificate image, or a screenshot as a substitute. Ask the supplier to provide the K number it believes is relevant to your proposed product.

2. Search FDA’s public 510(k) database

Open the FDA Premarket Notification database and search the K number. Record the device name, applicant, decision, product code, and available public documents. Use the applicant’s legal name exactly as shown rather than relying on a brand name or translated company name.

3. Compare the cleared device with the proposed private-label SKU

Request a written comparison covering at least:

scented or unscented format;
applicator or non-applicator construction;
design and dimensions;
absorbency categories and test basis;
component materials and any additives;
withdrawal string and other functional components;
individual wrapper and retail packaging changes;
instructions, warnings, claims, and intended users; and
manufacturing site and critical processes.

The comparison should identify differences, not simply state “same product.” A qualified regulatory reviewer should determine whether the proposed configuration fits the existing cleared device and whether any new submission or other action is needed.

4. Review the public 510(k) documents and controlled supplier evidence

Where available, review the decision letter and 510(k) summary or statement. Ask for controlled evidence that connects the offered SKU to the cleared configuration. Some technical documents may be confidential, so define an appropriate document-review or confidentiality process instead of accepting an unsupported conclusion.

5. Document the conclusion before artwork and mass production

Keep the comparison, regulatory assessment, approved specification, entity map, and label approval together. If the product or supply chain later changes, use the same file to determine what must be reassessed.

For a broader project overview, see our FDA requirements guide for private-label tampons.

Registration, listing, and clearance are different records

Record	What it addresses	What it does not prove by itself
Establishment registration	Identifies an establishment and its regulated activities for the applicable registration period.	That FDA has approved the facility or reviewed every device it handles.
Device listing	Associates a device with an establishment and its activities in commercial distribution.	That the exact private-label configuration is cleared or that all claims are acceptable.
510(k) clearance	FDA’s determination of substantial equivalence for the device described in a specific premarket notification.	A blanket approval of a company, every future variation, or every private-label claim.

This distinction matters in supplier marketing. A third-party “FDA registration certificate” is not evidence of product clearance. FDA says it does not issue device-registration certificates, and its registration database carries a notice that registration does not denote approval.

For buyer-facing copy, avoid a broad phrase such as “FDA approved factory” or “FDA-certified tampon.” Use precise, supportable language tied to the exact record and device, and have the final wording reviewed.

When can private-label changes affect the 510(k) pathway?

FDA’s guidance on changes to an existing device explains that manufacturers must assess whether a change could significantly affect safety or effectiveness or represents a major change in intended use. The conclusion depends on the exact device and cumulative changes, so it should not be made from a generic checklist alone.

For tampon projects, review changes involving:

design, dimensions, or construction;
component materials, additives, colorants, finishes, or processing;
absorbency performance or labeled absorbency category;
applicator design or material;
microbiological, biocompatibility, chemical-residue, integrity, string-strength, or fiber-shedding considerations;
intended use, instructions, warnings, or safety-related claims;
manufacturing site, process, or supplier changes that could affect the finished device; and
multiple smaller changes considered together.

A brand-name or graphic change may look commercial rather than technical, but the final labeling still has to meet applicable requirements. A labeling or packaging operation may also create a relabeler or repackager role even when a new 510(k) is not required. Separate the premarket-change analysis from establishment-registration, device-listing, and labeling obligations.

As of FDA’s July 6, 2026 menstrual-product page, the agency states that its 2025 tampon guidance is still a draft and that the July 2005 guidance remains current until the draft is finalized. Use current official sources at the time of your project review.

Put responsibilities into a written matrix

Before issuing a purchase order, turn verbal answers into an approved responsibility matrix.

Workstream	Named responsible party	Evidence to retain
Premarket pathway and change assessment	Exact legal entity and qualified reviewer	K number, database record, device comparison, signed assessment, and escalation process.
Establishment registration and device listing	Each entity responsible for its own required activity	Current database records, legal name and address, owner/operator details, and annual verification date.
Manufacturing and release	Physical facility and specification owner	Approved specification, quality agreement, process controls, test plan, batch-release criteria, and traceability records.
Labeling and artwork	Brand owner, regulatory reviewer, relabeler, or other named entity	Approved artwork, instructions, warnings, absorbency terminology, revision history, and sign-off.
Complaints and regulatory reporting	Manufacturer, importer, and any other responsible entity	Complaint-routing procedure, reporting assessment process, contacts, timelines, and record ownership.
Change control	Specification owner plus affected suppliers and regulatory reviewer	Written advance-notice requirement, change request, impact assessment, approval, and implementation record.
Importation	Initial importer and customs or logistics parties	Registered importer details, manufacturer identification, entry-data procedure, document set, and exception handling.
FDA communication for a foreign establishment	U.S. agent and foreign establishment	Appointment, current contact details, communication procedure, and escalation route.

The matrix should also state which party pays for new testing or regulatory work, who can approve a substitute material or facility, and what happens if a registration, listing, or clearance record changes.

Documents to request before packaging approval

Use a document checklist linked to the exact SKU and destination market:

Exact 510(k) number and FDA public database record.
Available 510(k) decision letter and summary or statement.
Written comparison between the cleared device and proposed private-label specification.
Legal names, addresses, and roles of the applicant, specification developer, manufacturer, relabeler or repackager, initial importer, and U.S. agent, as applicable.
Current establishment-registration and device-listing records for the relevant entities.
Finished product specification and component-level bill of materials.
Relevant performance, material, microbiological, biocompatibility, and other verification evidence for the proposed configuration.
Draft retail labeling, instructions, warnings, absorbency wording, and claims.
Quality agreement, change-control procedure, complaint-routing plan, and traceability responsibilities.
Import and distribution responsibility matrix.

For artwork planning across markets, review our tampon packaging regulations guide. For the broader OEM workflow, see private-label tampon manufacturing.

Common red flags during supplier due diligence

A supplier provides only a third-party registration certificate and will not provide an exact K number.
The K number belongs to a different device or applicant, and the supplier cannot explain the documented relationship.
The offered product differs in materials, construction, absorbency, applicator, or labeling, but no change assessment is available.
The seller cannot identify the physical facility or each entity’s registered activity.
“U.S. agent” and “initial importer” are treated as interchangeable without reviewing the actual activities.
Packaging carries “FDA approved” or “FDA certified” language unsupported by the specific regulatory status.
The contract does not assign change notification, labeling approval, complaints, reporting, import, or record-retention responsibilities.
The sales entity, invoice issuer, bank beneficiary, manufacturer, and document holder do not align and the differences are not explained.

Frequently asked questions

Does FDA establishment registration mean a tampon is FDA approved?

No. FDA states that registration and listing do not denote approval, clearance, or authorization of an establishment or its devices. For a tampon subject to premarket review, verify the exact device in the appropriate FDA database and assess its relevance to the proposed SKU.

Can a factory’s 510(k) automatically cover my private-label tampon?

Do not assume so. Verify the exact 510(k) record, applicant, cleared device, manufacturing relationship, and differences between that device and your proposed specification and labeling. A qualified regulatory professional should document the conclusion.

Is a U.S. agent the same as an initial importer?

No. A U.S. agent is the FDA communication contact for a foreign establishment. An initial importer is a U.S. entity performing a defined import and marketing role. One company could potentially perform both roles, but the roles and obligations remain distinct.

Does the private-label brand owner need to register with FDA?

It depends on the activities the brand owner performs. A company that develops specifications, changes labeling, repackages, manufactures, or initially imports may fall into a registrable role. Map the real activities and obtain project-specific advice instead of deciding from the brand name alone.

Can a packaging-only change require a new 510(k)?

The answer depends on what changes and whether it could affect the device’s identity, safety, effectiveness, or intended use. Even when a new 510(k) is not required, labeling, registration, listing, relabeler, or repackager obligations may still apply. Document both analyses.

Request a U.S. tampon project document review

Contact Green Gardener with your target U.S. sales route, tampon format, requested absorbencies, component materials, applicator preference, available K number or supplier documents, exact private-label changes, packaging concept, entity names, estimated quantity, timeline, and required-document checklist.

We can use that information to structure the product and documentation discussion. Final regulatory decisions should be confirmed by your qualified U.S. adviser for the exact project.